RAND Report Author’s Comments Show Bias, Ephedra Education Council Says
This article was originally published in The Tan Sheet
Executive Summary
Recent comments by Paul Shekelle, MD/PhD and RAND Corp. colleagues represent "a dramatic departure from the objective, peer-reviewed findings of the RAND report" on ephedra, according to Ephedra Education Council General Counsel Wes Siegner
You may also be interested in...
RAND Report Recommends Case-Control Ephedra Study Look At AE Risk
A case-control study examining the risk of serious adverse events related to the use of ephedra and ephedrine alkaloid-containing dietary supplements would fill a vital gap in the current body of research on the supplement ingredient, the RAND report states
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands